2. The falloff of effectiveness vs Omicron over time is striking. Here VE for age 50+ against mortality
3. Also seen vs hospitalizations by 10+ weeks
4. No difference in vaccine effectiveness between Omicron lineages BA.1 and BA.2 vs symptomatic disease, but steady decline at 10+ weeks
5. The UK has done an exceptional job in getting >90% people of advanced age boosted. The US stands at 65%
6. Unlike the UK, which has laid out its plan for a 4th dose, the US has no plan. Just like what happened for the 3rd dose. washingtonpost.com/opinions/2022/…
• • •
Missing some Tweet in this thread? You can try to
force a refresh
Just published @nature
The impact of #Covid on the brain: the 1st longitudinal imaging study before and after infection, with controls nature.com/articles/s4158…
Reduction of grey matter, brain size, cognitive decline
Demographics of Covid cases and controls. Only 15 of cases were hospitalized and results did not change when they were deleted from analysis
One of the most important studies of the pandemic; further work to determine reversibility needed. Credit @OxfordWIN@uk_biobank Gwenaelle Douaud and colleagues for this contribution
My new essay @guardian
"Why one-shot after a Covid-19 infection should suffice to be considered fully-vaxxed" theguardian.com/commentisfree/…
Summarizes extensive new evidence that confirmed Prior Covid ("Natural Immunity" or NI) + 1-shot is as protective as 3-shots /1
These 6 new reports (5 in the last week) all demonstrate that NI + 1-shot provides a consistent high level of added protection from reinfection, across multiple variants, which is not ameliorated by additional shots /2
I've reviewed considerable other new data here, such as the J&J vaccine randomized, placebo-controlled trial report last wk @NEJM which showed NI had superior protection vs moderate-to-severe Covid than 1-shot of the vaccine (90% vs 56%, respectively) erictopol.substack.com/p/ground-truth… /3
New @CDCgov
Proof of benefit of vaccine booster for protection from Covid hospitalization in young, age 18-49, as previously documented in other countries covid.cdc.gov/covid-data-tra…
77% reduction with 2-shots
94% reduction with booster
All ages, 18+
2-shot reduction of hospitalization 76%
3-shot reduction of hospitalization 93%
Remarkable consistency across age groups for reduction of hospitalization for 2-shot and booster vaccination vs unvaccinated
2-shot 3-shot
Age 18-49 77% 94%
Age 50-64 79% 92%
Age 65+ 74% 94%